Patent application number | Description | Published |
20130037215 | DEVICE FOR THE MASTER MOULDING TECHNIQUE PRODUCTION OF AN INTEGRAL STRUCTURAL COMPONENT MADE OF A FIBRE COMPOSITE MATERIAL REINFORCED BY STRINGERS FOR AN AIRCRAFT - A device for the master moulding technique production of an integral structural component made of a fibre composite for an aircraft that is reinforced by stringers includes at least one moulded part forming a mounting surface to create an exterior or interior surface of the structural component, onto which at least one channel for evacuation of the structural component covered by a vacuum film is arranged, with the structural component comprising a skin-like laminate and a plurality of stringers which are disposed spaced apart from one another, wherein at least surface sections between adjacent stringers are covered with an auxiliary stripe, which comprises a textile ventilation fleece which rests on a vacuum film, and a pre-assembled release film firmly connected therewith, the width (B | 02-14-2013 |
20130224443 | REINFORCEMENT DEVICE FOR THE PURPOSE OF REINFORCING A MAIN LOAD-BEARING COVERING PANEL AND MAIN LOAD-BEARING COVERING PANEL - The invention concerns a reinforcement device for the purpose of reinforcing a main load-bearing covering panel, also a corresponding main load-bearing covering panel, a structural component of a flow body, and also a corresponding flow body. Here the reinforcement device serves the purpose of accommodating and transferring forces and/or stresses in the interior of the covering panel. In accordance with the present invention, in addition to forces and/or stress in the normal direction, forces and/or stresses in a crosswise direction, that is to say, for example, transverse stresses and/or shear stresses, can also be accommodated and transferred. | 08-29-2013 |
20140141193 | METHOD AND APPARATUS FOR FORMING A CURVED PREPREG STRIP - The present invention relates to a method of forming a curved prepreg strip or sheet, especially for use in fabricating a composite component. The method includes providing a strip or sheet of prepreg material having reinforcing fibres and drawing or conveying the prepreg material in a travel direction, wherein the material is drawn or conveyed in the travel direction at a speed which differs across a width of the strip or sheet transverse to the travel direction. Similarly, the invention relates to an apparatus for forming a curved prepreg strip or sheet, having: a mechanism for drawing or conveying a strip or sheet of prepreg material in a travel direction, wherein the mechanism is configured to draw or convey the strip or sheet of prepreg material in the travel direction at a speed which differs across a width of the strip or sheet transverse to the travel direction. | 05-22-2014 |
20140306372 | Method And Apparatus For Producing A Fiber-Reinforced Plastics Casting - An apparatus and method for producing a fiber-reinforced plastics casting (FRP), includes a moulding box filled with free flowing moulding material, in what a prototype of casting or a textile preform is inserted, forming a mould cavity for infiltration the inserted preform of textile with synthetic resin material in order to form a fiber-reinforced plastics casting (FRP). | 10-16-2014 |
20150130109 | METHOD AND DEVICE FOR PRODUCING A TEXTILE PREFORM - A method for producing a textile preform includes manufacturing a multi-layer fiber fabric, which includes a first flange portion and a web portion connected to the first flange portion, deforming a first fiber layer of the first flange portion with respect to the web portion, such that the first fiber layer is at a first flange portion angle to the web portion, a web height of the web portion being set in a variable manner during the deformation of the first fiber layer, and depositing a unidirectional fiber fabric only on the deformed first fiber layer of the first flange portion. | 05-14-2015 |
Patent application number | Description | Published |
20080260680 | Method of Attenuating Reactions to Skin Irritants - The present invention is directed to a method of inhibiting CDld activation by administering a composition containing a moiety that blocks CDld activation. Compositions of the invention are useful for the attenuation of CDld-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration. | 10-23-2008 |
20110065605 | METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH - The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself. | 03-17-2011 |
20140286949 | METHOD OF ATTENUATING REACTIONS TO SKIN IRRITANTS - The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration. | 09-25-2014 |
20140322732 | METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH - The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself. | 10-30-2014 |
20160074423 | METHOD OF ATTENUATING REACTIONS TO SKIN IRRITANTS - The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration. | 03-17-2016 |